Interfakultäres Institut für Genetik und Funktionelle Genomforschung (UMG)
Refine
Year of publication
Document Type
- Doctoral Thesis (25)
- Article (21)
Has Fulltext
- yes (46)
Is part of the Bibliography
- no (46)
Keywords
- - (12)
- Proteomanalyse (9)
- Staphylococcus aureus (6)
- Proteomics (4)
- Infektion (3)
- SNP (3)
- host-pathogen interactions (3)
- proteomics (3)
- CRISPR/Cas9 (2)
- GWAS (2)
Institute
- Interfakultäres Institut für Genetik und Funktionelle Genomforschung (UMG) (46)
- Institut für Humangenetik (1)
- Institut für Immunologie u. Transfusionsmedizin - Abteilung Immunologie (1)
- Institut für Immunologie u. Transfusionsmedizin - Abteilung Transfusionsmedizin (1)
- Institut für Med. Biochemie u. Molekularbiologie (1)
Publisher
- MDPI (8)
- Frontiers Media S.A. (4)
- Wiley (3)
- S. Karger AG (2)
- Elsevier (1)
- Ferrata Storti Foundation (1)
- Taylor & Francis (1)
Staphylococcus aureus is a commensal colonizing 20-30% of the population as well as a pathogen causing diverse diseases ranging from skin infections via toxin mediated diseases to life threatening conditions. In its interplay with the human host, this microorganism resorts to an extensive repertoire of both membrane-bound and secreted virulence factors facilitating adhesion to, invasion of, and spreading into various host tissues. Among the numerous virulence factors produced by S. aureus are the staphylococcal superantigens (SAgs). They directly cross-link conserved regions of the T cell-receptor with MHC class II molecules (outside the peptide-binding cleft) on antigen presenting cells. This results in a strong stimulation of up to 20% of all T cells which respond with proliferation and massive cytokine release. Recently, the enterotoxin gene cluster (egc) located on a pathogenicity island was described. The egc-genes are the most prevalent SAg genes in commensal and invasive S. aureus isolates. However, they appear to cause toxic shock only very rarely and their presence is negatively correlated with severity of S. aureus sepsis. Therefore it was suggested that SAgs might differ in their pro-inflammatory potential. In addition to their superantigenicity, SAgs also act as conventional antigens and induce a specific antibody response. In contrast to non-egc SAgs, despite the high prevalence of egc SAgs, neutralizing antibodies against egc SAgs are very rare, even among carriers of egc-positive S. aureus strains. In order to find an explanation for this “egc-gap”, we have tested two non-exclusive hypotheses: (i) egc and non-egc SAgs have unique intrinsic properties and drive the immune response into different directions and (ii) egc and non-egc SAgs are released by S. aureus under different conditions, which shape the immune response to them. To test these hypotheses, we compared the effects of egc and non-egc SAgs on human blood cells. Their T cell-mitogenic potencies, the elicited cytokine profiles as well as their impact on gene expression were highly similar. Both egc and non-egc SAgs induced a very strong pro-inflammatory response. In contrast, the regulation of SAg release by S. aureus differed markedly between egc and non-egc SAgs. Egc-encoded proteins were secreted by S. aureus during exponential growth, while non-egc SAgs were released in the stationary phase. We conclude that the distinct biological behavior of egc and non-egc SAgs is not due to their intrinsic properties, which are very similar, but is caused by their differential release by S. aureus. Traditionally, S. aureus has not been considered as an intracellular pathogen but strong evidence emerged indicating that staphylococci can invade and persist in various cell types. Internalization might constitute a bacterial strategy to evade the host’s defense reactions and the action of antibiotics. The intracellular niche might thus constitute a reservoir for chronic or relapsing infections. Contrary to their potential importance, genome-wide functional genomics analyses of the adaptation reactions of S. aureus to the host cell environment are rare and so far confined to gene expression profiling. Investigations addressing the proteome of internalized S. aureus are still lacking due to the challenge of obtaining a sufficient number of infecting bacteria. The proteome of other pathogens such as Francisella tularensis has been characterized by classical 2-DE approaches. However, the number of bacteria required for such a 2-DE based approach is often exceeding the numbers available from in vivo infection models. Furthermore, this approach does not allow monitoring of time-dependent quantitative changes in protein levels. Here, a workflow allowing time-resolved analysis of internalized S. aureus by combining pulse-chase stable isotope labeling by amino acids in cell culture with high capacity cell sorting, on-membrane digestion, and high-sensitivity mass spectrometry is presented. This workflow permits detection and quantitative monitoring of several hundred staphylococcal proteins from as little as a few million internalized S. aureus cells. This approach has been used to reveal time-resolved changes in levels of proteins in S. aureus RN1HG upon internalization by human bronchial epithelial cells. Proteins involved in stress adaptation as well as protein folding and some components of the phosphotransferase system were upregulated in internalized staphylococci, whereas proteins of the purine biosynthesis pathway and tRNA aminoacylation were downregulated. Furthermore, regulatory adaptive responses of internalized S. aureus to the intracellular milieu were shown as global regulators displayed increased protein abundance levels compared to non-internalized bacteria. Taken together, we observed changes in levels of proteins with functions in protection against oxidative damage and adaptation of cell wall synthesis in internalized S. aureus.
Genome-wide association studies (GWAS) are used to identify genetic markers linked with at least partially heritable diseases or phenotypes without prior knowledge of any disease-associated genetic loci. In summer 2008, all individuals of the population based cohort Study of Health in Pomerania (SHIP) were individually genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 microarray. The aim of this work was to establish an efficient workflow for GWAS using the more than 4000 individually genotyped samples of the SHIP cohort as well as pooled samples, focusing exclusively on analyzing genetic variations based on single nucleotide polymorphisms (SNPs). Firstly, an optimal array platform for the genotyping analysis had to be chosen that detected most of the available genetic variants at a high level of accuracy. Secondly, extensive quality controls had to be performed starting from DNA extraction and including tests of the generated array data by the analysis software to obtain the most reliable data for the subsequent association studies. For the identification of loci with smaller genetic influences, individual cohorts were meta-analyzed in large nationally and internationally organized consortia (e.g. CHARGE, BPGen, HaemGen, GIANT, CKD Gen). To participate in those meta-analyses, a comparable common set of genetic data had to be generated. This was done by imputation of the data generated by individual array-based genotyping on the basis of a reference panel using chromosomal linkage information. Due to the extensive phenotype information in the SHIP study, it was possible to perform many genome-wide discovery analyses and replication studies of possible susceptibility loci in a short time once the genetic data was available and processed. This resulted in the necessity to set up an efficient workflow for storing the huge amount of genetic data, converting it into different formats readable for specific analysis software, performing the association analyses and processing the results into a human-readable and clear format. This included replications, GWAS and meta-analyses of several cohorts. Many susceptibility loci were newly identified in different association studies with the SHIP data included and were subsequently published. In this work, genetic association studies with the SHIP data included were performed and published on blood pressure, uric acid concentrations, cardiac structure and function, lipid metabolism, hematological parameters, kidney functions, smoking quantity, circulating IGF-I and IGFBP-3 concentrations and thyroid volume including the risk of goiter development. Besides the SHIP cohort, there was a need to use other, especially patient cohorts for GWAS. Since no genotype information from these patient cohorts was available and the individual genotyping of many probands is still expensive and therefore often not affordable, we established the cost-effective allelotyping method that relied on pooling of DNA samples prior to the hybridization with microarrays. After estimating the pooling-specific error of a case-control allelotyping study, the allelotyping approach was used for identifying genetic susceptibility loci associated with aggressive periodontitis. If not referring to work of collaborators, all statistical analyses, data handling and in silico work concerning the SHIP data described in this context was performed by the author of this dissertation.
Macrophages are cells of immune system and distributed throughout the body. They provide the first line of defense against microbial pathogen infections. Using bone marrow macrophages (BMMs) which derived from mice of strain BALB/c and strain C57BL/6, this study aimed to identify the changes in proteome of the macrophages due to IFN gamma stimulation and S. aureus infection. Two quantitative proteomic techniques, two-dimensional difference gel electrophoresis (2D-DIGE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) were applied in this study. The analysis results indicated that many proteins which play important roles in immunological functions of macrophages were changed due to IFN gamma stimulation and S. aureus infection. This study also identified the differences in proteome of macrophages derived from mice of strain BALB/c in comparing to macrophages of strain C57BL/6.
In the post genomic era, novel “Omics” technologies like genomics and proteomics can be used in powerful screening approaches to provide unbiased lists of candidate genes and proteins and thus facilitate a comprehensive analysis of complex diseases such as cancer, which would not have been possible applying traditional genetic and biochemical approaches alone. During my PhD tenure I applied functional genomics screening technologies including proteomics in combination with traditional biochemical and cell biology approaches in two disease oriented projects: 1. Characterization of the role of BCL11b in Human T cell lymphomas (and) 2. Elucidation of the mechanism of pathophysiology of Johanson Blizzard Syndrome using UBR1 knockout mice and JBS patients’ lymphoblasts cell lines.
1.Characterization of the role of BCL11b in Human T cell lymphomas
: The Bcl11b protein belongs to the C2H2-family of Krueppel-like zinc finger proteins and thus is a member of the largest family of transcription factors in eukaryotes. It was shown to be important for a variety of functions such as T cell differentiation, normal development of central nervous system and DNA damage response. Malignant T cells undergo apoptotic cell death upon BCL11B down-regulation. However, the detailed mechanism of this cell death is not fully understood. Two dimensional difference in-gel electrophoresis (2D-DIGE), mass spectrometry and cell biological experiments were employed to investigate the functional impact of knock down of BCL11B in malignant T cell lines such as Jurkat and huT78. To further confirm the findings of these experiments, changes in protein patterns were also recorded after down-regulation of BCL11B expression in Jurkat cells over expressing BcL-xL and in Jurkat cells over expressing BCL11B. These experiments provide evidence for the involvement of the mitochondrial apoptotic pathway and increased levels of cleavage fragments of known caspase targets such as myosin, spectrin and vimentin were observed after BCL11B knockdown. The findings suggest an involvement of ERM proteins, which were up-regulated and phosphorylated upon BCL11B down-regulation. Besides ERM proteins, PDCD5, a key regulator of apoptosis, was also found at increased levels upon down regulation of BCL11B. Moreover, the levels of several proteins implicated in cell cycle entry, including DUT-N, UCK2, MAT1, CDK6, MCM4 and MCM6 were elevated, which might lead to uncontrolled cell cycle progression, uracil misincorporation and cell death. Interestingly, an inverse regulation pattern, i.e. decreased levels of ERM proteins, DUT-N, UCK2 and PDCD5 was seen upon over expression of BCL11B in Jurkat cells. In summary, proteome analyses revealed several previously unidentified mechanisms which could significantly contribute to the cell death following BCL11B knockdown.
2.Elucidation of the mechanism of pathophysiology of Johanson Blizzard Syndrome using UBR1 knockout mice and JBS patients’ lymphoblasts cell lines
: Johanson-Blizzard syndrome (JBS; OMIM 243,800), which was first described in 1971, is a rare autosomal recessively inherited genetic disorder with a unique combination of congenital abnormalities. The most constant clinical feature of JBS is the loss of exocrine pancreatic function due to progressive destruction of pancreatic acini. Genome wide linkage analysis identified the disease associated locus in the 15q14-q21 chromosome region and high-throughput sequencing of this region revealed several truncated and some missense mutations in the UBR1 gene. UBR1 gene contains 47 exons and spans over 161 kilobases. The UBR1 protein belongs to the E3 ubiquitin ligase family and is an important component of the N-end rule pathway of ubiquitous protein degradation. It was hypothesized that stabilization of direct and unique substrates of UBR1 could be the main cause of the JBS pathophysiology. So far sequencing of the UBR1 gene is the only available diagnostic procedure. However, sequencing might not always allow precise prediction of residual UBR1 activity. Hence, this study was started to develop a protein based diagnostic assay for the detection of subclinical cases of JBS and to identify signalling pathways contributing to the pathophysiology of this complex disorder using a murine UBR1 knockout model. 2D-DIGE proteome analysis was carried out for a comparative evaluation of lymphoblast samples of 14 patients and 11 controls. Principal component Analysis (PCA) clearly discriminated JBS patients from controls. However, 4 JBS patients differed from the rest and resembled controls more closely. Western-blot analysis revealed residual UBR1 levels in these patients, which were linked to a milder phenotype. Hierarchical clustering of the three groups (controls, patients with residual UBR1 levels and patients without UBR1) showed group-specific characteristic differences in the abundance of differentially regulated proteins. Quantification of a panel of five selected protein spots encompassing Interferon-induced GTP binding protein, HLA class II histocompatibility antigen, Annexin A6, FK506-binding protein 4 and GRP78 permitted discrimination of controls and JBS patients with mild phenotypes. Of note, the molecular chaperones GRP78 (BiP) and FK506BP were consistently altered in level in JBS patients and probably constitute UBR1 dependent substrates. This suggested JBS as an ER-stress related disease also indicating a possible way of therapeutic intervention. Comparative proteome analysis of UBR1 knockout and wild type animals after caerulein treatment revealed a significant accumulation of pancreatic proteases such as chymotrypsin B, anionic trypsin and pancreatic elastase in animals lacking UBR1. Furthermore, an up-regulation of ER-stress proteins and inflammation related proteins was observed. Phenotypic characterisation revealed in UBR1 knockout animals significantly increased lipase levels, a significantly increased histological score and significantly increased elastase activity 8h after the onset of pancreatitis. In isolated pancreatic acini of UBR1 knockout animals we found a significant increase in intracellular elastase activation upon supramaximal CCK stimulation, which was associated with a significant rise in the rate of necrosis explaining the more severe phenotype in the UBR1 knock-out animals. A TUNEL assay showed that there was more apoptosis in wild type compared to UBR1 knockout mice. Another set of experiments was designed to identify physiologically important substrates of UBR1. Inhibition of such substrates might then in turn allow reversion or prevention of the severe form of pancreatitis in UBR1 knockout mice. However, using the trypsin specific and reversible inhibitor S-124 it was shown that impaired trypsin degradation and thereby prolonged activation of this protease did not critically influence the phenotype. Calcium analysis after physiological stimulation revealed an increase of pathological Ca2+ signalling events, i.e. significant decrease of spike number and significant increase of spike duration. Of the candidates potentially influencing Ca2+ signalling RGS4 turned out to be of particular importance. Pre-incubation of pancreatic acini of UBR1 knockout animals with a specific RGS4 inhibitor (CCG-4986, 10 µM) normalized Ca2+ patterns, did not affect trypsin activity itself but prevented Ca2+-triggered premature trypsin activation and thus acinar disintegration. In summary, using lymphoblasts samples of JBS patients we were able to deduce a protein panel which could be developed as a possible diagnostic tool for confirmation of JBS syndrome. Furthermore, using UBR1 knockout mice in an experimental model we were able to elucidate the vital function of UBR1 and its direct substrate RGS4 in the defense against pathologic pancreatic damage thereby manifesting JBS as an inflammatory disorder due to an inadequate UBR1 mediated defense.
Myokardiale Erkrankungen gehören zu den häufigsten Todesursachen. Das Verständnis der molekularen, patho-physiologischen Ereignisse ist somit entscheidend für die Suche nach geeigneten Therapien. Um einen Einblick in zelluläre Ereignisse der kardialen Erkrankungen zu erhalten, sollten in der hier vorgelegten Arbeit Genexpressionsanalysen unter Verwendung von DNA-Mikroarrays durchgeführt werden. Den Schwerpunkt dieser Arbeit bildete die Charakterisierung der Immunadsorptionstherapie (IA/IgG-Therapie), die eine Therapieoption der dilatativen Kardiomyopathie (DCM) darstellt. Anhand von Genexpressionsanalysen immunadsorbierter Patienten sollte der Therapieeffekt analysiert werden. Dafür wurde zunächst die Etablierung eines Protokolls zur Isolation von Protein und RNA aus humanen endomyokardialen Biopsien von DCM-Patienten nötig. Um die mit der Therapie verbundenen Genexpressionsänderungen einordnen zu können, sollte zunächst das Genexpressionsmuster von 47 DCM-Patienten mit Patienten ohne Einschränkung der Pumpfunktion (Kontrollen) verglichen und mittels Real-time PCR validiert werden. Die Betrachtung dieser DCM-Patienten und Patienten, die eine normale Pumpfunktion aufwiesen, ergab 649 Gene mit krankheitsbedingt veränderter Expression. Zu diesen gehören neben bekannten Herzinsuffizienz-Markern (BNP, ANP, MYH6) Gene, die Proteine des Protein-Ubiquitinylierungssystem kodieren oder an der Ausprägung von Hypoxie und Fibrose (Connective tissue growth factor) beteiligt sind und auf eine Dysregulation des Proteinabbaus, erhöhten oxidativen Stress und Matrix-Remodeling hinweisen. Darüber hinaus ist aufgrund der geringeren Expression von Genen, die der oxidativen Phosphorylierung und Glykolyse zuzuordnen sind, von einer Energielimitation in DCM-Patienten auszugehen. Unter Berücksichtigung von verschiedenen klinischen Parametern bestand weiterhin die Aufgabe, den Einfluss dieser Parameter auf die Genexpression zu klären. Während wenig Korrelationen zu Body-Mass-Index (BMI), Alter und Krankheitszeitraum auftrat, wurde eine Häufung von Genen festgestellt, deren Expression zur LVEF und LVIDd korreliert. Gene, die Regulatoren mit myokardialer Funktion kodieren (ADRA1A, ADRB2, PLN, RYR2), zeigten gleichzeitig Korrelationen zur LVEF und dem LVIDd (p<0,05). Darüber hinaus sollte das Genexpressionsprofil von Patienten, die von der IA/IgG-Therapie profitieren (Responder) mit den Patienten ohne Therapieerfolg (Nonresponder) vor und 6 Monate nach der IA/IgG-Therapie verglichen werden. In der Subgruppe der Responder wurde für 171 Gene eine signifikant unterschiedliche Expression bestimmt, während die Zahl der durch die Therapie in ihrer Expressionshöhe betroffenen Gene in Nonrespondern mit 72 wesentlich geringer ausfiel. Gene, die sowohl in Respondern nach Therapie als auch krankheitsbedingt verändert waren, konnten kaum beobachtet werden, so dass andere Mechanismen für den Therapieeffekt verantwortlich sein müssen. Neben einer geringeren Expression des ACE2 wurde auch eine Abnahme Fibrose-assoziierter Gene wie CTGF, Fibronectin und Collagen 1A2 in Respondern nach IA/IgG-Therapie beobachtet. Zudem war eine signifikante LVIDd-Abnahme in Respondern zu verzeichnen, die in Nonrespondern nicht zu erkennen war. In Nonrespondern wurde nach IA/IgG-Therapie dagegen die verminderte Expression einiger Komplementfaktoren beobachtet. Zudem bestand die Aufgabe in der Suche nach Genexpressionsänderungen immunadsorbierter DCM-Patienten, die mit der Änderung klinischer Parameter korrelieren. Weiterhin sollte im Rahmen dieser Arbeit eine beschreibende Signatur definiert werden, die eine Vorhersage des Therapieerfolges für den individuellen DCM-Patienten vor Durchführung der IA/IgG-Therapie ermöglicht. Unter Verwendung des Resamplings (Crossvalidierung) wurde mit Hilfe einer Support Vector Machine eine Signatur von 25 Genen definiert, die eine Klassifizierung der Subgruppen mit einer Fehlerrate von 3,7% erlaubt. Die in Abhängigkeit verschiedener, myokardialer Parameter gezeigten Genexpressionsunterschiede in DCM-Patienten spiegeln die Dynamik der Erkrankung wider. Der Einfluss der IA/IgG-Therapie auf die Genexpression von Patienten, die an der DCM erkrankt sind, betrifft eine Vielzahl von Genen verschiedener Kategorien. Korrelationsanalysen zeigen, dass ein Zusammenhang zwischen Genexpressionsänderung und den Änderungen der Parameter LVEF, LVIDd und Inflammation bestehen. Mit der Definition von Patienten, die von der IA/IgG-Therapie profitieren, wurden auch Unterschiede bezüglich klinischer Parameter (LVIDd, Zeitraum der Erkrankung) deutlich, die zum Verständnis der hier dargestellten Genexpressionsunterschiede beitragen. Die generierten Daten bieten neben dem besseren Verständnis der im Myokard ablaufenden Prozesse eine Reihe von Ansatzpunkten für weitere Untersuchungen, wie zum Beispiel zur Rolle des IGF-1-Signalweges oder des Protein-Ubiquitinylierungssystems bei der Ausprägung der DCM, die auch zu neuen Therapieansätzen beitragen können.
Medulloblastoma is one of the most common malignant childhood brain tumors. Although advances in multimodal treatment have significantly improved the survival rate, the outcome of children is still very poor. Therefore, there is an urgent need to develop novel approaches that can increase survival and reduce long term side effects of patients. Histone deacetylase inhibitors (HDIs) have emerged as a promising new class of antineoplastic agents in cancer therapy. Among them, suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza®) is a highly potential HDI which has been approved for treatment of cutaneous T-cell lymphoma and is currently used for treatment of various tumor cell types both in vivo and in vitro. However, only little information has been reported on the effects of SAHA on primary central nervous system (CNS) tumors including medulloblastoma. The DAOY cell line represents the most widely used model cell line for investigation of medulloblastoma. In a recent study, it was reported that SAHA induces apoptosis and cell cycle arrest of DAOY cells (Sonnemann et al., 2006). However, the molecular mechanisms underlying this antitumor activity are still not clear. Therefore, in this study, effects of SAHA on DAOY cells were analysed at the protein level by using both gel-based and gel-free proteomic approaches. A 2D proteome reference map of DAOY cells in pH range of 4-7 was created from control and 10 µM SAHA treated cells via a combined analysis using 2D electrophoresis and MALDI-TOF/TOF-MS. This reference map covers 1196 identified protein spots of more than 770 distinct proteins. This is the first report of a 2D proteome map of SAHA treated DAOY cells. Moreover, the number of covered proteins was increased with the aid of a 1D-RP-LC-ESI-MS/MS analysis. Both methods together gave rise to a total of over 1200 distinct protein species, which is the largest catalogue of proteins identified in DAOY cells so far. In SAHA treated cells, a series of proteins were found to be subjected to protein degradation after treatment with the drug, including mainly cytoskeleton proteins (e.g. beta-tubulin, beta/gamma-actin, vimentin, filamin interacting protein 1), heat shock protein HS90B and a component of the FACT chromosomal remodelling complex (SSRP1). Most of those proteins are known substrates for caspases. Interestingly, several of these protein degradations are reported as typical apoptotic events in brain cells such as fragmentations of lamin A/C, alpha-spectrin, myosin-9 and SSRP1. The 2D reference map was then used as an annotated database for further investigation of changes in protein expression and protein modification profiles of DAOY cells following SAHA treatment. By using the 2D-DIGE technique, SAHA was found to induce significant changes in protein levels of DAOY cells, especially at the concentration of 10 µM while considerably fewer changes in the protein pattern were observed after treatment with the lower dose of 2 µM. Quantitative analysis of total protein extracts using the 2D-DIGE technique (employing pH range of 4-7) and spectral counting (employing a 1D-RP-LC separation) resulted in the identification of 213 differentially expressed proteins after treatment with 10 µM SAHA. Most of the targeted proteins belong to the groups of cytoskeleton proteins (e.g. lamin B1, calreticulin, dynexin), heat shock proteins (e.g. HSP71, HSP7C, CH60, GRP78) and brain signal transductors (e.g. 14-3-3E, 14-3-3T, CRK, MARCS). Other proteins that changed in levels after SAHA treatment include proteins involved in chromatin remodelling (e.g. RUBV1, RUBV2), transcription regulation (e.g. YBOX, CBX5), redox regulation (e.g. TXND4, TXND5, BIEA), metabolism (e.g. G6PI, K6PP, LDHB) and RNA processing (HNRP K). In addition, cathepsin D, one of autophagic executors, was increased by SAHA treatment while different subunits of the 26S proteasome complex were decreased in levels after addition of SAHA. Interestingly, we found alterations of mitochondrial proteins indicating the perturbation of mitochondrial function. VDACs are pore forming proteins located on the outer mitochondrial membrane which is known to play an important role in the release of apoptogenic proteins such as cytochrome-c from mitochondria to cytoplasm and induction of apoptosis. In this study, VDAC1 and VDAC3 were found to be overexpressed after incubation with SAHA, which might lead to an extensive release of apoptogenic proteins. This result is consistent with the study of Sonnemann and co-workers showing that SAHA induced the mitochondrial apoptotic pathway of DAOY cells (Sonnemann et al., 2006). Furthermore, these results are also in agreement with the previously known antitumor activities of SAHA reported for other cancer cell lines, e.g. the up-regulation of heat shock proteins, prostaglandin synthase 3, ubiquinol cytochrome c reductase or the down-regulation of MARCS proteins. …………………